Certara

CERT · NASDAQ

$9.79+$0.335 (+3.54%)TodayMarket closed ·
Prev close $9.45

About CERT

Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. The company is headquartered in Radnor, Pennsylvania and currently employs 1,515 full-time employees. The company went IPO on 2020-12-11. The company accelerates medicine using biosimulation software, technology and services to transform traditional drug discovery and development. The company delivers software products and technology-driven services to customers to carry out and realize the full benefits of biosimulation in drug discovery, preclinical and clinical research, regulatory submissions and market access. Its regulatory science and market access software and services, such as regulatory submissions software, natural language processing and Bayesian analytics. The company offers both mechanistic and empirical biosimulation solutions providing clients with a comprehensive offering based on their therapy goals, mechanism of action, and available data sources. Its clients include 2,400 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries.

Employees
1,515
Headquarters
Radnor, Pennsylvania
Listed
Dec 11, 2020
Sector
Health Care
Industry
Health Care Technology

Leadership

Certara executives
NameTitleSince
James Cashman——
Leif Pedersen——
Jon Resnick—2026
John Gallagher——
Robert Aspbury——
Adrian Mckemey——
Rona Anhalt——
Daniel Corcoran——
Eran Broshy——
Cynthia Collins——
Rosemary Crane——
Nancy Killefer——
Stephen Mclean——
John Reynders——
David Spaight——
Matthew Walsh——

Revenue by product and region

Fiscal year ended Dec 31, 2025: $418.84M total revenue

By region

  • Americas$291.60M69.6%
  • EMEA$92.63M22.1%
  • Asia Pac$34.61M8.3%

Similar companies

Companies in the same industry as Certara

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.